Genmab — Marts 2020
-
Upfront multidrug regimens prove beneficial in Myeloma. https://www.onclive.com/web-exclusives/upfront-multidrug-regimens-prove-beneficial-in-myeloma
-
-
Dr. Raje on the efficacy of Belantamab Mafodotin in Multiple Myeloma. https://www.onclive.com/onclive-tv/dr-raje-on-the-efficacy-of-belantamab-mafodotin-in-multiple-myeloma
-
Sutro har et BCMA ADC under udvikling i samarbejde med BMS (tidligere Celgene), hvor man forventer at bivirkningsprofilen vil være markant bedre end GSKs BCMA ADC, da man anvender site specific conjugation. Sutro´s to egne ADC´er i klinikken har indtil videre ikke vist occular toxicity. Forventningen er at stoffet skal kunne gives på community centers ! Blot en lille reklame for Sutro
-
Nu 1558..:-(
-
Det er svært at være daytrader i disse tider...nogle dage skal man starte ud med bull andre dage bear. Men hvis man rammer er der penge i Genmab.
-
Ja i tredie linie er det. Vincent Rajkumar har på Twitter meddelt at han vil bruge Sarclisa i Pom/Dex kombien hvis det er billigere...
-
Sarclisa er kun godkendt til tredie linie plus patienter, så i første og anden linie er det ikke en trussel, og det er langt det største marked
-
Nogen der ved hvornår Sarclisa kan blive godkendt i 1. og 2. linie?
-
- linje dette her fase 3 - Ikema: https://www.clinicaltrials.gov/ct2/show/NCT03275285?term=isatuximab+mm&draw=2&rank=4
-
Det eneste 1. linje jeg har kunnet finde er dette fase 1: https://www.clinicaltrials.gov/ct2/show/NCT02513186?term=isatuximab+mm&draw=2&rank=2
-
Tak Bulder
-
this NKTCL trial was recently completed; should we expect a Ph III trial to be started? https://clinicaltrials.gov/ct2/show/NCT02927925?term=NKTCL+AND+daratumumab&draw=2&rank=1
-
There were some years ago stories about fantastic outcome for some patients with NKTCL who received dara. But since then it has been quite.
-
Conclusions: DARA 16 mg/kg was well tolerated with no new safety concerns, and only 2 patients discontinuing due to TEAEs. DARA monotherapy demonstrated an encouraging response rate (ORR: 25%) in pts with R/R NKTCL and warrants further study in this poor prognosis pt population. https://ashpublications.org/blood/article/134/Supplement_1/1568/427350/Daratumumab-Monotherapy-for-Patients-with-Relapsed
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind